Asia Pacific Rare Neurological Disease Treatment Market Drivers and Forecasts by 2027

The Asia Pacific rare neurological disease treatment market is expected to reach US$ 2,437.02 Mn in 2027 from US$ 1,225.38 Mn in 2019. The market is estimated to grow with a CAGR of 9.2% from 2019-2027.

The growth of the market is driven by factors such as the rising prevalence of rare neurological diseases, increasing awareness about rare diseases, and robust pipeline drugs in the Asia Pacific region. However, higher cost of rare neurological disease treatments is likely to restrain the market growth to a certain extent.

A large group of rare diseases that have inefficient diagnoses and treatments are the neurological disease. These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body. There is no surety regarding the onset of the diseases; some can strike during childhood, whereas others can affect even highly aged people.

Rapid developments in healthcare and drug discovery are leading to the introduction of new therapeutic solutions for the treatment of rare neurological diseases. Authorities such as World Health Organization are taking constructive steps to encourage the research activities to find a remedy for rare neurological disease treatment. For instance, in recent decades, considerable attention has been paid worldwide to stimulate the research, development and marketing of medicinal products for rare diseases. In Singapore, Axsome Therapeutics, Inc. is developing revolutionary therapies for central nervous system disorders (CNS), namely AXS-12 for narcolepsy treatment. Additionally, increasing prevalence of rare neurological diseases is expected to drive the growth of the rare neurological disease treatment market during the forecast period.

The frequency of neurological disorders has increased significantly across Asia Pacific. These disorders are estimated to affect over a billion population, according to the World Health Organization in 2016. Neurological disorders are commonly found among population, irrespective of the age groups, and geographic region. In the recent years, various measures have been implemented to generate awareness and educate the population regarding rare neurological diseases, which is facilitating patients to access the suitable medications and treatments for these conditions. Factors such as rising incidences of chronic illnesses, an increase in the aging population, and pediatric care, are boosting the growth of the healthcare industry. The increasing awareness among patients and developing healthcare infrastructure are likely to offer significant opportunity for the growth of the market.

The increasing use of rare neurological disease treatment in medical treatment cases in Asia Pacific is expected to drive rare neurological disease treatment market the growing pharmaceuticals industry in the country create a lucrative opportunity and the presence of an established market for rare neurological disease treatment.

Rest of Asia Pacific Rare neurological disease treatment Market Revenue and Forecasts to 2027 (US$ Bn)

ASIA PACIFIC RARE NEUROLOGICAL DISEASE TREATMENT – MARKET SEGMENTATION

Asia Pacific Rare Neurological Disease Treatment Market - By Indication

• Narcolepsy
• Amyotrophic Lateral Sclerosis
• Alzheimer’s Disease
• Multiple Sclerosis
• Spinal Muscular Atrophy (SMA)
• Duchenne Muscular Dystrophy
• Other Indications

Asia Pacific Rare Neurological Disease Treatment Market - By Drug Type

• Organic Compounds
• Biologics

Asia Pacific Rare Neurological Disease Treatment Market - By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Asia Pacific Rare Neurological Disease Treatment Market - By Mode of Administration

• Oral
• Injectable

Asia Pacific Rare Neurological Disease Treatment Market - By Country

• Japan
• China
• India
• Australia
• South Korea

Companies Mentioned

• Allergan plc.
• Bayer AG
• GlaxoSmithKline plc.
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd
• Takeda Pharmaceutical Company Limited

Asia Pacific Rare Neurological Disease Treatment Report Scope